KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Research & Development (2023 - 2025)

Biocryst Pharmaceuticals' Research & Development history spans 9 years, with the latest figure at $40.9 million for Q4 2025.

  • For Q4 2025, Research & Development fell 17.34% year-over-year to $40.9 million; the TTM value through Dec 2025 reached $166.1 million, down 4.87%, while the annual FY2025 figure was $166.1 million, 4.87% down from the prior year.
  • Research & Development reached $40.9 million in Q4 2025 per BCRX's latest filing, down from $44.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $162.9 million in Q4 2023 to a low of $37.3 million in Q1 2025.
  • Average Research & Development over 3 years is $56.0 million, with a median of $43.4 million recorded in 2025.
  • Peak YoY movement for Research & Development: plummeted 69.64% in 2024, then rose 15.32% in 2025.
  • A 3-year view of Research & Development shows it stood at $162.9 million in 2023, then tumbled by 69.64% to $49.4 million in 2024, then dropped by 17.34% to $40.9 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Research & Development are $40.9 million (Q4 2025), $44.6 million (Q3 2025), and $43.4 million (Q2 2025).